

## Stereochemistry of the Dehydrogenation of (2*S*)-Histidine in the Biosynthesis of Roquefortine and Oxaline

By ROBERT VLEGGAR\* and PHILIPPUS L. WESSELS



(National Chemical Research Laboratory, Council for Scientific and Industrial Research, P.O. Box 395, Pretoria 0001, Republic of South Africa)

**Summary** A comparison of spectral data indicates the *E* configuration for the dehydrohistidine unit in both roquefortine and oxaline; incorporation of (2*S*,3*S*)- and (2*S*,3*R*)-[3-<sup>3</sup>H]histidine into roquefortine by *Penicillium roqueforti* and into oxaline by *Penicillium oxalicum* proceeded in each case with removal of the *pro-S* hydrogen atom from C(3).




NUMEROUS  $\alpha\beta$ -dehydroamino acids have in recent years been recognised as constituents of metabolites derived from micro-organisms<sup>1</sup> and one, dehydroalanine, has been identified at the active site of the enzyme histidine ammonia-lyase<sup>2,3</sup> and (2*S*)-phenylalanine ammonia-lyase.<sup>4</sup> Only a few studies, however, have been reported on the stereochemical course of the *in vivo* formation of  $\alpha\beta$ -dehydroamino acids.<sup>5-7</sup>

The recent isolation and structure elucidation of the neurotoxin roquefortine (1) from cultures of *Penicillium roqueforti*<sup>8</sup> and our work on the structure of oxaline (2), a metabolite isolated from *Penicillium oxalicum*,<sup>9,10</sup> prompted us to investigate the stereochemistry of the dehydrogenation of (2*S*)-histidine in these two metabolites.

X-Ray crystallography<sup>9</sup> and <sup>13</sup>C n.m.r. spectroscopy<sup>10</sup> established the *E* configuration for the 12,15 double bond in oxaline (2). The signal due to C(13) (166.1 p.p.m.) in the



coupled nuclear Overhauser enhanced  $^{13}\text{C}$  n.m.r. spectrum of (2) appears as a doublet with  $^3J(\text{CH})$  10.0 Hz. The magnitude of  $^3J(\text{CH})$  is indicative of the *E* configuration.<sup>6,7,11</sup> The assignment of the natural abundance  $^{13}\text{C}$  n.m.r. spectrum of roquefortine (1) derived from coupled, proton noise decoupled, and selective proton decoupled spectra and selective population inversion experiments<sup>12</sup> is given in Table 1 and enabled us to determine the hitherto unknown 3,17 double bond configuration. The value of 8.6 Hz for  $^3J(\text{CH})$  between C(4) and H(17) favours the *E* configuration for roquefortine. This result was verified as follows. The  $^{13}\text{C}$  n.m.r. assignments of the reported<sup>13</sup> photoproduct of roquefortine, for which the trivial name 'isoroquefortine' (3) is suggested, are given in Table 1. The magnitude of  $^3J(\text{CH})$  between C(4) and H(17), 4.7 Hz is indicative of the *Z* configuration for the 3,17 double bond as shown in (3). This result is in agreement with the 4.9 Hz for  $^3J(\text{CH})$  observed between C(4) and H(10) in viridamine (4)<sup>14</sup> which has the *Z*-configuration.<sup>15</sup>



In order to determine which of the two diastereotopic hydrogens at C(3) of (2*S*)-histidine is removed in the dehydrogenation reaction samples of (2*S*,3*S*)- and (2*S*,3*R*)-[ $^3\text{H}$ ]-histidine, (5a) and (5b), respectively were prepared from 4(5)-[formyl- $^3\text{H}$ ]formylimidazole.<sup>16</sup> The two samples were each mixed with (2*S*)-[ring-2'- $^{14}\text{C}$ ]histidine as an internal standard, to give the desired  $^3\text{H}:^{14}\text{C}$  ratios and crystallised to constant activity. The configurational purity of the (2*S*,3*R*)-[ $^3\text{H}$ ]-histidine (5b) sample ( $^3\text{H}:^{14}\text{C}$  6.50) was assayed using histidine ammonia-lyase (E.C.

4.3.1.3), an enzyme which stereospecifically eliminates the 3-*pro-R* hydrogen atom together with ammonia to give urocanic acid ( $^3\text{H}:^{14}\text{C}$  0.44;  $^3\text{H}$  retention: 6.8%).<sup>17</sup>

TABLE 1.  $^{13}\text{C}$  n.m.r. data for roquefortine (1) and isoroquefortine (3)

	(1) $\delta(\text{c})/\text{p.p.m.}^{\text{a}}$	(3) $\delta(\text{c})/\text{p.p.m.}^{\text{a}}$
C(1)	166.7S	165.4S
C(3)	121.9S	125.7S
C(4)	159.2S	158.2S
C(6)	78.3D	77.8D
C(8)	149.8S	150.2S
C(9)	109.1D	109.0D
C(10)	128.9D	128.8D
C(11)	119.0D	118.7D
C(12)	125.0D	125.0D
C(13)	128.5S	128.7S
C(14)	61.5S	61.6S
C(15)	36.8T	37.3T
C(16)	58.8D	59.0D
C(17)	110.9D	105.6D
C(18)	125.5S	136.8S
C(20)	136.4D	135.3D
C(22)	134.3D	117.7D
C(23)	40.9S	40.9S
C(24)	143.2D	143.4D
C(25)	114.5DD	114.4DD
C(26)	22.9Q	23.0Q
C(27)	22.5Q	22.5Q

<sup>a</sup> Relative to internal  $\text{Me}_4\text{Si}$

Each of the two substrates (5a) and (5b) was fed to cultures of *P. roqueforti* HPB 061175 and *P. oxalicum* MRC 100. Good incorporations (1–4%) of the substrates into both roquefortine and oxaline were observed. The results (Table 2) indicate that the 3-*pro-S* hydrogen of (2*S*)-histidine is stereospecifically eliminated in each case whereas tritium from the 3-*pro-R* position is retained. The dehydrogenation step in the biosynthesis of both roquefortine and oxaline must involve the *syn* elimination of H(2) and the *pro-S* hydrogen at C(3) of (2*S*)-histidine.

TABLE 2. Incorporation of [ $^3\text{H}$ ]histidine into roquefortine (1) and oxaline (2)

Configuration	$^3\text{H}:^{14}\text{C}$ ratio	(1) $^3\text{H}:^{14}\text{C}$ ratio	(2) $^3\text{H}:^{14}\text{C}$ ratio
2 <i>S</i> ,3 <i>S</i> (5a)	6.50	0.30 (4.6) <sup>a</sup>	0.30 (4.6)
2 <i>S</i> ,3 <i>R</i> (5b)	6.50	6.12 (94.2)	6.24 (96.0)

<sup>a</sup> Figures in brackets are %  $^3\text{H}$  retention.

Stereospecific *syn* elimination of the 3-*pro-S* hydrogen has been observed for (2*S*)-tyrosine in the biosynthesis of mycelianamide,<sup>5</sup> for the incorporation of (2*S*)-tryptophan into cryptochinuline A<sup>6</sup> and in the side-chain dehydrogenation of *N*-Boc-(2*S*)-tryptophan.<sup>7</sup> In each case the dehydroamino acid unit formed has the *Z* configuration. The hydrogen atom which is eliminated in the above quoted studies<sup>5–7</sup> is not the same as the one which is lost from C(3) of histidine in the biosynthesis of roquefortine and oxaline, although it is designated as 3-*pro-S* in all these instances.

The close biogenetic relationship between roquefortine and oxaline is indicated by the occurrence of roquefortine

together with oxaline in cultures of *P. oxalicum*.<sup>18</sup> The precursor rôle of roquefortine in oxaline biosynthesis is under investigation.

We thank Dr. P. M. Scott for the culture of *P. roqueforti*.

(Received, 30th October 1979; Com. 1155.)

- <sup>1</sup> U. Schmidt, J. Häusler, E. Öhler, and H. Poisel, *Progr. Chem. Org. Nat. Prod.*, 1979, **37**, 251.
- <sup>2</sup> J. L. Givot, T. A. Smith, and R. H. Abeles, *J. Biol. Chem.*, 1969, **244**, 6341.
- <sup>3</sup> R. B. Wickner, *J. Biol. Chem.*, 1969, **244**, 6550.
- <sup>4</sup> K. R. Hanson and E. A. Havir, *Arch. Biochem. Biophys.*, 1970, **141**, 1.
- <sup>5</sup> G. W. Kirby and S. Narayanaswami, *J.C.S. Chem. Comm.*, 1973, 322; *J.C.S. Perkin I*, 1976, 1564.
- <sup>6</sup> R. Cardillo, C. Fuganti, D. Ghireghelli, P. Grasselli, and G. Gatti, *J.C.S. Chem. Comm.*, 1975, 778.
- <sup>7</sup> M. E. Gustafson, D. Miller, P. J. Davis, J. P. Rosazza, C.-J. Chang, and H. G. Floss, *J.C.S. Chem. Comm.*, 1977, 842.
- <sup>8</sup> P. M. Scott, M.-A. Merrien, and J. Polonsky, *Experientia*, 1976, **32**, 140.
- <sup>9</sup> D. W. Nagel, K. G. R. Pachler, P. S. Steyn, P. L. Wessels, G. Gafner, and G. J. Kruger, *J.C.S. Chem. Comm.*, 1974, 1021.
- <sup>10</sup> D. W. Nagel, K. G. R. Pachler, P. S. Steyn, R. Vleggaar, and P. L. Wessels, *Tetrahedron*, 1976, **32**, 2625.
- <sup>11</sup> J. A. Stubbe and G. L. Kenyon, *Biochemistry*, 1971, **10**, 2669; J. L. Marshall and R. Seiwel, *J. Magnetic Resonance*, 1974, **15**, 150; C. A. Kingsbury, D. Draney, A. Sopchik, W. Rissler, and D. Durham, *J. Org. Chem.*, 1976, **41**, 3863; E. P. Prokof'ev and E. I. Karpeiskaya, *Tetrahedron Letters*, 1979, 737.
- <sup>12</sup> K. G. R. Pachler and P. L. Wessels, *J. Magnetic Resonance*, 1977, **28**, 53.
- <sup>13</sup> P. M. Scott and B. P. C. Kennedy, *J. Agric. Food Chem.*, 1976, **24**, 865.
- <sup>14</sup> R. Vleggaar and P. L. Wessels, unpublished results.
- <sup>15</sup> C. W. Holzappel and J. J. Marsh, *S. African J. Chem.*, 1977, **30**, 197; A. Dippenaar, C. W. Holzappel, and J. C. A. Boeyens, *ibid.*, p. 161.
- <sup>16</sup> A. R. Battersby, M. Nicoletti, J. Staunton, and R. Vleggaar, *J.C.S. Perkin I*, 1980, 43.
- <sup>17</sup> Ref. 2. Note that their conclusions must be reversed since they were based upon the supposed stereospecificity of fumarate hydratase which was then incorrectly assigned; J. Rétey, H. Fierz, and W. P. Zeylemaker, *F.E.B.S. Letters*, 1970, **6**, 203.
- <sup>18</sup> R. Vleggaar, unpublished results.